The purpose of this study is to prove that luteal phase supplementation with recombinant LH can solve the luteal phase deficiency after Gnrh agonist oocytes triggering in women at risk of OHSS

开始日期2013-06-30

申办/合作机构-

EUCTR2010-022032-37-IT

/ Not yet recruitingN/A

Randomized, open-label, single centre study on ovarian stimulation in ART poor responders treated with recombinant FSH in association with recombinant LH.

开始日期2011-03-18

申办/合作机构

Casa di Cura Abano Terme Polispecialistica e Termale SpA

NCT01457703

/ CompletedN/AIIT

Reproductive Hormonal Alterations in Obesity, AIMS #1 & #2

The purpose of this study is to determine why obese women have lower hormone levels and less fertility than women of normal body weight. The proposal will examine the reproductive system at the level of the brain and the ovary to define the changes that happen leading to lowered hormone production. Women will be studied throughout a menstrual cycle and given medications that will test how well their pituitary gland can make hormones that stimulate the ovary (luteinizing hormone (LH) and follicle stimulating hormone (FSH)). They will also be given a medication to abolish estrogen production in the body and their response to this medication will be assessed. Finally, the ovary's ability to produce progesterone after ovulation will be examined.
--Hypotheses:
Obese women have reduced pituitary sensitivity to exogenous gonadotropin-releasing hormone (GnRH), but normal clearance of exogenous LH. (comparative study of obese compared to normal weight women)
Obese women have abnormally increased sensitivity to estradiol negative feedback which will be reversed by an aromatase inhibitor. (comparative study of obese compared to normal weight women)

开始日期2010-06-01

申办/合作机构

University of Colorado Denver

[+1]

100 项与 Recombinant LH(San Carlo Public Hospital, Potenza, Italy) 相关的临床结果

登录后查看更多信息

100 项与 Recombinant LH(San Carlo Public Hospital, Potenza, Italy) 相关的转化医学

登录后查看更多信息

100 项与 Recombinant LH(San Carlo Public Hospital, Potenza, Italy) 相关的专利（医药）

登录后查看更多信息

116

项与 Recombinant LH(San Carlo Public Hospital, Potenza, Italy) 相关的文献（医药）

2024-10-01·Human Reproduction

Undetected, natural conception pregnancies in luteal phase stimulations—case series and review of literature

Article

作者: Del Gallego, R ; Edades, J ; Kalafat, E ; Fatemi, H ; Ata, B ; Selim, S ; Lawrenz, B

AbstractSTUDY QUESTIONWhat is the risk of an undetected natural conception pregnancy during luteal phase ovarian stimulation, and how does it impact the pregnancy's course?SUMMARY ANSWERThe risk for an undetected, natural conception pregnancy in luteal phase ovarian stimulation is low and it appears that ovarian stimulation is unlikely to harm the pregnancy.WHAT IS KNOWN ALREADYRandom start ovarian stimulation appears to be similarly effective as early follicular stimulation start; and it allows ovarian stimulation to be started independent of the cycle day and throughout the cycle, in accordance with the patients’ and clinics’ schedule as long as there is no intention of a fresh embryo transfer in the same cycle. Starting ovarian stimulation in the luteal phase bears the possibility of an—at the timepoint of stimulation start—undetected, natural conception pregnancy that has already occurred. There is scarce data on the incidence of this event as well as on the possible implications of ovarian stimulation on the course of an existing pregnancy.STUDY DESIGN, SIZE, DURATIONThis retrospective observational study, performed between June 2017 and January 2024, analyzed luteal phase stimulations, in which a natural conception pregnancy was detected during the ovarian stimulation treatment for IVF/ICSI. Luteal phase stimulation was defined as ovarian stimulation started after ovulation and before the next expected menstrual bleeding, with a serum progesterone (P4) level of >1.5 ng/ml on the day of stimulation start or 1 day before.PARTICIPANTS/MATERIALS, SETTING, METHODSWomen who underwent a luteal phase ovarian stimulation in a tertiary referral ART center.MAIN RESULTS AND THE ROLE OF CHANCEA total of 488 luteal phase stimulation cycles were included in the analysis. Luteal phase stimulation was only started after a negative serum hCG measurement on the day or 1 day before commencement of ovarian stimulation. Ten patients (2.1%) had an undetected natural conception pregnancy at the time of luteal phase stimulation start. Eight of these patients underwent an ovarian stimulation in a GnRH-antagonist protocol and two in a progestin-primed stimulation protocol (PPOS). Recombinant FSH was used as stimulation medication for all patients, the patients with a PPOS protocol received additional recombinant LH. One pregnancy (0.2%) was detected after the oocyte retrieval, the other nine pregnancies were detected either due to persistent high serum progesterone levels or due to an increasing progesterone level after an initial decrease before oocyte retrieval. In the cycles with an undetected natural conception pregnancy, the median number of stimulation days was 8 days (range: 6–11 days) and median serum hCG at detection of pregnancy was 59 IU hCG (range: 14.91–183.1). From 10 patients with a pregnancy, three patients delivered a healthy baby, two patients had ongoing pregnancies at the time of summarizing the data, three patients had biochemical pregnancies (patient age: 30, 39, and 42 years), one patient had an ectopic pregnancy which required a salpingectomy, and one patient (age: 34 years) had an early pregnancy loss.LIMITATIONS, REASONS FOR CAUTIONThe retrospective study design and the small sample size can limit the accuracy of the estimates.WIDER IMPLICATIONS OF THE FINDINGSOverall, there is a small risk of undetected natural conception pregnancies when luteal phase stimulation is undertaken. It appears that there are no adverse effects through either direct effect on the embryo or indirectly through a detrimental effect on the corpus luteum function on the pregnancy in our cohort.STUDY FUNDING/COMPETING INTEREST(S)This study did not receive funding. The authors declare that there is no conflict of interest.TRIAL REGISTRATION NUMBERN/A.

2021-12-01·Reproductive Biology and Endocrinology2区 · 医学

Recombinant follicular stimulating hormone plus recombinant luteinizing hormone versus human menopausal gonadotropins- does the source of LH bioactivity affect ovarian stimulation outcome?

2区 · 医学

ArticleOA

作者: Lebovitz, O ; Orvieto, R ; Zilberberg, E ; Nahum, R ; Gil, O ; Haas, J ; Kirshenbaum, M

AbstractObjectiveLuteinizing hormone (LH) and human chorionic gonadotropin (hCG) activate distinct intracellular signaling cascades. However, due to their similar structure and common receptor, they are used interchangeably during ovarian stimulation (OS). This study aims to assess if the source of LH used during OS affects IVF outcome.Patients and methodsThis was a cross sectional study of patients who underwent two consecutive IVF cycles, one included recombinant follicular stimulating hormone (FSH) plus recombinant LH [rFSH+rLH, (Pergoveris)] and the other included urinary hCG [highly purified hMG (HP-hMG), (Menopur)]. The OS protocol, except of the LH preparation, was identical in the two IVF cycles.ResultsThe rate of mature oocytes was not different between the treatment cycles (0.9 in the rFSH+rLH vs 0.8 in the HP-hMG, p = 0.07). Nonetheless, the mean number of mature oocytes retrieved in the rFSH+rLH treatment cycles was higher compared to the HP-hMG treatment cycles (10 ± 5.8 vs 8.3 ± 4.6, respectively, P = 0.01). Likewise, the mean number of fertilized oocytes was higher in the rFSH+rLH cycles compared with the HP-hMG cycles (8.5 ± 5.9 vs 6.4 ± 3.6, respectively, p = 0.05). There was no difference between the treatment cycles regarding the number of top-quality embryos, the ratio of top-quality embryos per number of oocytes retrieved or fertilized oocytes or the pregnancy rate.ConclusionThe differences in treatment outcome, derived by different LH preparations reflect the distinct physiological role of these molecules. Our findings may assist in tailoring a specific gonadotropin regimen when assembling an OS protocol.

2021-12-01·Reproductive BioMedicine Online3区 · 医学

Cumulus cell microRNA expression when LH is added to the ovarian stimulation protocol: a pilot study

3区 · 医学

Article

作者: Carvalho, Cristina V ; Bonetti, Tatiana C S ; Rodrigues, Fernanda ; Fraietta, Renato ; Vigo, Francieli Maria ; Motta, Eduardo L A

RESEARCH QUESTIONRecombinant FSH administration in ovarian stimulation for IVF is a standard procedure, whereas the role of LH is controversial. MicroRNAs (mRNA) are small endogenous non-coding transcripts that are involved in the regulation of many cellular processes, including foliculogenesis and gonadotrophin function. The aim was to study the possible role of miRNA in ovarian follicular development in groups having different ovarian stimulation protocols. Are there different miRNA expression profiles in cumulus cells of infertile women undergoing IVF? What are the regulated pathways?DESIGNThis prospective observational study included 13 patients who fulfilled the following inclusion criteria: younger than 38 years of age; a tubal infertility factor; a male factor; or idiopathic infertility. This is a pilot study in which the patients were aleatory enrolled into two groups: seven in FSH group (recombinant FSH, 225 IU) and six in FSH plus LH group (recombinant FSH, 150 IU + recombinant LH, 75 IU). The granulosa cells obtained from the follicular ovarian retrieval were analysed using polyerase chain reaction. Results were analysed using DIANA Tools, an online bioinformatics tool.RESULTSAmong the 84 microRNAs evaluated, 11 were differentially expressed between the groups, all of which were upregulated in the FSH plus LH group, compared with the FSH group. Differentially expressed miRNA profiles are related to oestrogen signalling, oocyte meiosis and pluripotent cells regulation.CONCLUSIONmiRNA overexpression in the FSH plus LH group is consistent with the independent and fundamental role of LH in folliculogenesis, leading to a distinct molecular response between groups.

100 项与 Recombinant LH(San Carlo Public Hospital, Potenza, Italy) 相关的药物交易

登录后查看更多信息

研发状态

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


Bicetre Hospital (ESPE2022)	N/A	卡尔曼综合征	18	rhLH and rhFSH CSI	(齋糧餘構鑰衊壓襯鏇廠) = 壓網窪網醖繭窪壓顧鑰憲積構觸製願簾膚膚網 (製艱鬱鑰顧遞鏇鏇遞蓋 )	积极	2022-09-15
				recombinant LH	(齋糧餘構鑰衊壓襯鏇廠) = 憲壓獵淵窪膚範廠鹽製憲積構觸製願簾膚膚網 (製艱鬱鑰顧遞鏇鏇遞蓋 )
NCT01457703 (CTgov)	N/A	肥胖	62	Recombinant LH+Cetrorelix+Letrozole+Gonadorelin-GnRH (BMI ≥30 kg/m2)	遞憲鏇選窪製糧醖壓窪(築築鹹鹽蓋選鹹獵糧鬱) = 醖製夢獵膚淵製選餘壓製廠獵鏇衊構糧簾網遞 (鹹鏇鬱繭顧蓋襯簾齋醖, 鏇糧餘網餘齋艱遞窪糧 ~ 積淵選網鏇衊觸憲遞醖) 更多	-	2015-03-25
				Recombinant LH+Cetrorelix+Letrozole+Gonadorelin-GnRH (BMI 18-25 kg/m2)	遞憲鏇選窪製糧醖壓窪(築築鹹鹽蓋選鹹獵糧鬱) = 醖廠夢淵選淵蓋獵壓鬱製廠獵鏇衊構糧簾網遞 (鹹鏇鬱繭顧蓋襯簾齋醖, 夢遞憲窪齋糧憲蓋艱艱 ~ 繭獵齋構廠窪憲鏇簾遞) 更多